Search results for "Subcutaneous"

showing 10 items of 162 documents

Lipoic acid lessens Th1-mediated inflammation in lipopolysaccharide-induced uveitis reducing selectively Th1 lymphocytes-related cytokines release

2013

AbstractInflammation results in the production of free radicals. We evaluated the anti-inflammatory and antioxidant capacity of lipoic acid in an experimental uveitis model upon a subcutaneous injection of endotoxin into Lewis rats. The role of oxidative stress in the endotoxin-induced uveitis model is well-known. Besides, the Th1 response classically performs a central part in the immunopathological process of experimental autoimmune uveitis. Exogenous sources of lipoic acid have been shown to exhibit antioxidant and anti-inflammatory properties. Our results show that lipoic acid treatment plays a preventive role in endotoxin-induced oxidative stress at 24 h post-administration and reduced…

LipopolysaccharidesMaleAntioxidantantioxidantLipopolysaccharidemedicine.medical_treatmentInflammationPharmacologymedicine.disease_causeBiochemistryAntioxidantsUveitischemistry.chemical_compoundSubcutaneous injectionmedicineAnimalsInflammationTh1 lymphocytesTh2 lymphocytesThioctic AcidChemistryAnti-Inflammatory Agents Non-SteroidalGeneral MedicineTh1 Cellsmedicine.diseaselipoic acidcytokinesRatsCellular infiltrationLipoic acidDisease Models AnimalRats Inbred LewImmunologyuveitisCytokineslipids (amino acids peptides and proteins)medicine.symptomOxidative stressUveitis
researchProduct

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

2014

Background & Aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency. Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD)…

Liver Cirrhosismedicine.medical_specialtyTime FactorsBiologyInfusions SubcutaneousSeverity of Illness IndexArticleHepatitischemistry.chemical_compoundAcyl-CoAMethionineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsRNA MessengerMice Knockoutchemistry.chemical_classificationHepatologyFatty acid metabolismFatty AcidsFatty liverGastroenterologyFatty acidmedicine.diseaseRecombinant ProteinsCholine DeficiencyFibroblast Growth FactorsMice Inbred C57BLDisease Models AnimalEndocrinologyLiverchemistryLipotoxicityDisease ProgressionLipid PeroxidationInflammation MediatorsSteatosisLong chain fatty acidOxidation-ReductionGastroenterology
researchProduct

Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats

2021

Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N-acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain homeostasis of the glutamate system disrupted in addiction. However, there is little evidence in the case of alcohol. The aim of this study was to explore the potential anti-relapse efficacy of NAC using the alcohol deprivation effect (ADE) model in long-term experienced rats. Two experiments were performed in male Wistar rats to: (a) test the effic…

Male0301 basic medicineDrugAlcohol DrinkingInjections Subcutaneousmedia_common.quotation_subjectDrug Evaluation PreclinicalAlcoholPharmacologyInfusions Subcutaneous:CIENCIAS DE LA VIDA [UNESCO]ethanol relapse preventionAcetylcysteineRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundSubcutaneous injection0302 clinical medicinePharmacotherapyalcohol use disordersRecurrenceglutamate neurotransmissionUNESCO::CIENCIAS DE LA VIDAAnimalsMedicineRats Wistarmedia_commonEthanolEthanolbusiness.industryAbstinencealcohol deprivation effecAcetylcysteineRatsSubstance Withdrawal SyndromeAlcoholismRegimen030104 developmental biologychemistryModels Animalbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

2018

BACKGROUND: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases characterized by recurrent fever flares. METHODS: We randomly assigned patients with genetically confirmed colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, or TRAPS at the time of a flare to receive 150 mg of canakinumab subcutaneously or placebo every 4 weeks. Patients who did not have a resolution of their flare received an add-on injection of 150 mg of canakinumab. The primary outcome was complete response (resolution…

Male0301 basic medicineInterleukin-1betaFamilial Mediterranean fever0302 clinical medicineMonoclonalChildMedicine(all)Mevalonate kinase deficiencySubcutaneousMedicine (all)Interleukin-1betaAntibodies MonoclonalGeneral MedicineFamilial Mediterranean FeverRecurrent feverChild PreschoolFemaleTumor necrosis factor alphaDrugInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drugAdultAdolescentFeverInjections SubcutaneousHereditary Autoinflammatory DiseasesAntibodies Monoclonal HumanizedAdolescent; Adult; Antibodies Monoclonal/administration & dosage; Antibodies Monoclonal/adverse effects; Antibodies Monoclonal/therapeutic use; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever/drug therapy; Female; Fever/drug therapy; Hereditary Autoinflammatory Diseases/drug therapy; Humans; Injections Subcutaneous; Interleukin-1beta/antagonists & inhibitors; Male; Mevalonate Kinase Deficiency/drug therapy; Young AdultAntibodiesInjectionsDose-Response RelationshipYoung Adult03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodGeneral & Internal MedicinemedicineHumansPreschoolAdolescent; Adult; Antibodies Monoclonal; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever; Female; Fever; Hereditary Autoinflammatory Diseases; Humans; Injections Subcutaneous; Interleukin-1beta; Male; Mevalonate Kinase Deficiency; Young Adult; Medicine (all)030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryHereditary Autoinflammatory DiseasesHyperimmunoglobulinemia Dmedicine.diseaseCanakinumab030104 developmental biologyImmunologyMevalonate Kinase Deficiencybusiness
researchProduct

The complex alteration in the network of IL-17-type cytokines in patients with hereditary angioedema

2018

Hereditary angioedema (HAE) is a rare autosomic-dominant disorder characterized by a deficiency of C1 esterase inhibitor which causes episodic swellings of subcutaneous tissues, bowel walls and upper airways that are disabling and potentially life-threatening. We evaluated n = 17 patients with confirmed HAE diagnosis during attack and remission state and n = 19 healthy subjects. The samples were tested for a panel of IL (Interleukin)-17-type cytokines (IL-1β, IL-6, IL-10, granulocyte–macrophage colony stimulating factor (GM-CSF), IL-17, IL-21, IL-22, IL-23) and transforming growth factor-beta (TGF-β) subtypes. Data indicate that there are variations of cytokine levels in HAE subjects compar…

Male0301 basic medicinemedicine.medical_treatmentC1 esterase inhibitorInterleukin-23chemistry.chemical_compoundSubcutaneous TissueTransforming Growth Factor betaChildHereditary angioedemaHematologyInterleukin-17InterleukinGeneral MedicineMiddle AgedIntestinesCytokineHereditary angioedemaFemaleInterleukin 17medicine.symptomComplement C1 Inhibitor ProteinAdultmedicine.medical_specialtyAdolescentBradykininBronchiBradykininGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesInternal medicinemedicineHumansCytokineAgedBiochemistry Genetics and Molecular Biology (all)Angioedemabusiness.industryInterleukinsAngioedemas HereditaryGranulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseColony-stimulating factor030104 developmental biologyGene Expression RegulationchemistryCase-Control StudiesImmunologyTh17 CellsbusinessClinical and Experimental Medicine
researchProduct

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

2017

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the …

Male:aminoácidos péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]0301 basic medicine:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Enzims proteolítics - InhibidorsSelf AdministrationSeverity of Illness Indexlaw.inventionC1-inhibitorSubcutaneous injection0302 clinical medicineRandomized controlled triallawCross-Over StudiesHereditary Angioedema Types I and IIbiologyEdema - PrevencióGeneral Medicine:Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas Hereditary [DISEASES]AnesthesiaHereditary angioedema:Other subheadings::Other subheadings::/administration & dosage [Other subheadings]Female:Amino Acids Peptides and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS]medicine.symptomComplement C1 Inhibitor Protein:enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES]AdultRiskmedicine.medical_specialtyInjections Subcutaneous:Aminoácidos Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]Placebo:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumans:Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections Subcutaneous [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores]Dose-Response Relationship DrugAngioedemabusiness.industry:Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Injeccions hipodèrmiquesmedicine.diseaseCrossover studyClinical trial:terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]030104 developmental biology030228 respiratory systembiology.proteinbusinessNew England Journal of Medicine
researchProduct

Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion

2012

Despite the efficacy in reducing acute rejection events in organ transplanted subjects, long term therapy with cyclosporine A is associated with increased atherosclerotic cardiovascular morbidity. We studied whether this drug affects the antiatherogenic process of the reverse cholesterol transport from macrophages in vivo. Cyclosporine A 50 mg/kg/d was administered to C57BL/6 mice by subcutaneous injection for 14 days. Macrophage reverse cholesterol transport was assessed by following [(3)H]-cholesterol mobilization from pre-labeled intraperitoneally injected macrophages, expressing or not apolipoprotein E, to plasma, liver and feces. The pharmacological treatment significantly reduced the …

MaleApolipoprotein EMouselcsh:MedicineCardiovascularBiochemistryFecesMiceSubcutaneous injectionchemistry.chemical_compoundIntestinal Mucosalcsh:ScienceCholesterol 7-alpha-HydroxylaseMultidisciplinaryReverse cholesterol transportAnimal ModelsLipidsIntestinesCholesterolLiverCyclosporineMedicinelipids (amino acids peptides and proteins)Research Articlemedicine.medical_specialtyLipoproteinsTritiumCholesterol 7 alpha-hydroxylaseCardiovascular PharmacologyExcretionApolipoproteins EModel OrganismsIn vivoInternal medicinemedicineAnimalsBiologyCholesterollcsh:RProteinsBiological TransportLipid MetabolismAtherosclerosisSitosterolsSterolMice Inbred C57BLKineticsEndocrinologyGene Expression RegulationchemistryMacrophages Peritoneallcsh:QATP-Binding Cassette TransportersPLoS ONE
researchProduct

Epiphany root canal sealer prepared with resinous solvent is irritating to rat subcutaneous tissues.

2011

Objective: This study assessed the biocompatibility of the Epiphany endodontic sealer prepared with resinous solvent of Epiphany system (Thinning resin) in rat subcutaneous tissues. Study Design: Polyethylene tubes were filled with the sealer and 4 groups were established: GI, Epiphany prepared with 1 drop of resinous solvent (RS); GII, Epiphany prepared with 1 drop of RS and photoactivated; GIII, Epiphany associated with self-etch primer and prepared with 1 drop of RS; GIV, Epiphany associated with self-etch primer, prepared with 1 drop of RS and photoactivated. The filled tubes were implanted into 4 different regions of the dorsum of 20 adult male rats. Results: After 7, 14 and 21 days, a…

MaleBiocompatibilityAdult maleRoot canalmedia_common.quotation_subjectDentistryEndodonticsRoot Canal Filling MaterialsSubcutaneous TissueMaterials TestingmedicineAnimalsRats WistarGeneral Dentistrymedia_commonInflammationChemistrybusiness.industryChronic inflammatory reaction:CIENCIAS MÉDICAS [UNESCO]Epiphany sealerRatsSolventResins Syntheticmedicine.anatomical_structureOtorhinolaryngologyEpiphanyUNESCO::CIENCIAS MÉDICASSolventsSurgeryResearch-ArticlebusinessSubcutaneous tissueMedicina oral, patologia oral y cirugia bucal
researchProduct

Biocompatibility of a chlorhexidine local delivery system in a subcutaneous mouse model

2011

Made available in DSpace on 2013-08-12T19:11:10Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-03-01 Made available in DSpace on 2013-09-30T18:34:50Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-03-01 Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-20T14:04:50Z No. of bitstreams: 0 Made available in DSpace on 2014-05-20T14:04:50Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-03-01 Objective: This study aimed evaluating histologically and histomorphometrically the response of the conjunctive tissue face to the implant of chlorhexidine chips in the subcutaneous tissues of rats. Study Design: In this research 35 male rats Wistar wer…

MaleBiocompatibilityDentistryBiocompatible Materialschlorhexidine toxicityMiceDrug Delivery SystemsSubcutaneous Tissueparasitic diseasesmedicinedrug delivery systemAnimalsRats WistarperiodontitisGeneral DentistryPeriodontitisbusiness.industryChlorhexidineChlorhexidine:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseBiocompatible materialRatsOtorhinolaryngologyModels AnimalUNESCO::CIENCIAS MÉDICASAnti-Infective Agents LocalBiocompatibilitySurgeryDelivery systembusinessmedicine.drug
researchProduct

Classical Flt3L-dependent dendritic cells control immunity to protein vaccine

2014

DCs are critical for initiating immunity. The current paradigm in vaccine biology is that DCs migrating from peripheral tissue and classical lymphoid-resident DCs (cDCs) cooperate in the draining LNs to initiate priming and proliferation of T cells. Here, we observe subcutaneous immunity is Fms-like tyrosine kinase 3 ligand (Flt3L) dependent. Flt3L is rapidly secreted after immunization; Flt3 deletion reduces T cell responses by 50%. Flt3L enhances global T cell and humoral immunity as well as both the numbers and antigen capture capacity of migratory DCs (migDCs) and LN-resident cDCs. Surprisingly, however, we find immunity is controlled by cDCs and actively tempered in vivo by migDCs. Del…

MaleCellular immunityInjections IntradermalLangerinOvalbuminInjections SubcutaneousT cellImmunologyAntigen presentationGene ExpressionPriming (immunology)Mice Transgenicchemical and pharmacologic phenomenaLigandsInterferon-gammaMice03 medical and health sciences0302 clinical medicineAntigenT-Lymphocyte SubsetsImmunitymedicineAnimalsHumansImmunology and AllergyLectins C-Type030304 developmental biologyMice KnockoutAntigen PresentationVaccines0303 health sciencesbiologyMembrane ProteinsProteinsDendritic Cellsbiochemical phenomena metabolism and nutritionImmunity Humoral3. Good healthMice Inbred C57BLMannose-Binding Lectinsmedicine.anatomical_structureAntigens SurfaceHumoral immunityImmunologybiology.proteinbacteriaFemaleTranscription Factors030215 immunologyJournal of Experimental Medicine
researchProduct